Incubate Coalition
Making Medicine
There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of...
Be sure to visit the podcast's website and support the creator: www.spreaker.com
Author
Incubate Coalition
Category
Podcast website
Latest episode
Nov 19, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Inside Congress: Senator Thom Tillis on Drug Pricing, IP, and the Future of Innovation 04.12.2025 29:12
In this episode of Making Medicine, host John Stanford sits down with Senator Thom Tillis, the first sitting U.S. Senator to join the show. Tillis opens up about his relationship with President Trump, the impact of Most Favored Nation (MFN) drug pricing on U.S. innovation, and the forces shaping America’s biotech competitiveness. They discuss why predictable intellectual property and regulatory fr...
Making Medicine ft. Daphne Zohar. Biotech Flywheels, Policy Risks, and the Future of Innovation 25.11.2025 37:09
In this episode of the Making Medicine Podcast, John Stanford sits down with Daphne Zohar, Founder, CEO, and Board Member of Seaport Therapeutics to explore the forces shaping today’s biotech ecosystem. Daphne shares her entrepreneurial path from PureTech to Seaport, offering a rare inside look at building companies, catalyzing innovation, and scaling breakthrough science. The conversation dives i...
Japan’s Life Sciences State of Play: The Takeaways You Can’t Miss 20.11.2025 40:21
In this special Tokyo edition of the Making Medicine Podcast , John Stanford hosts a powerhouse panel of biotech investors, founders, and industry leaders to break down Japan’s emerging life-sciences boom. Together, they explore Japan’s regulatory shifts, government incentives, and rising startup momentum. This episode unpacks how Japan is positioning itself as a global hub for regenerative medic...
Inside Biotech Leadership: Bill Newell on Innovation, Capital, and Policy at Sutro Biopharma 13.11.2025 27:57
Former Sutro Biopharma CEO Bill Newell joins host John Stanford to discuss the realities of leading a biotech company through economic uncertainty, long development timelines, and a shifting policy landscape. Bill shares lessons from 16 years at the helm, raising over $1.6 billion, navigating clinical trials, and building partnerships with global pharma leaders. The episode dives deep into the cha...
U.S. Biomanufacturing Surge, Arena BioWorks Fallout & GLP-1 Rumors | Making Medicine Podcast 06.11.2025 18:18
In this episode, John Stanford breaks down the surge in U.S. biomanufacturing investments, including Virginia’s new $500B hub, and what it means for the nation’s workforce. He contrasts this expansion with the recent closure of Arena BioWorks, raising questions about the balance between onshoring and sustaining innovation. The discussion also dives into major rumors of a potential Medicare-GLP-1 d...
Is the U.S. Losing Its Biotech Edge to China? Senate Hearing & Innovation Outlook 30.10.2025 18:41
In this episode of Making Medicine, host John Stanford unpacks the Senate HELP Committee hearing on “The Future of Biotech.” From China’s accelerating investment to U.S. policy uncertainty, he explores what’s needed to protect American leadership in life sciences. The episode also covers new White House biosimilar announcements, gene therapy market challenges, and early insights from Incubate Poli...
FDA Vouchers, Orphan Cures & IP with Joshua Kresh 23.10.2025 25:03
In this week’s episode, John breaks down the White House headlines, the FDA’s new wave of priority review vouchers, and September approvals, then celebrates National IP Month with guest Joshua Kresh. We dig into criteria for the new wave of CNPVs, domestic manufacturing pushes (Augmentin XR and ketamine), and why some approvals matter for patients who’ve run out of options. John also unpacks the O...
Shutdown Fallout, MFN Deals & BIOSECURE Returns 16.10.2025 18:10
In this week’s episode, John Stanford breaks down Day 15 of the federal shutdown’s impact on health agencies, major pullbacks in cell & gene therapy, and the White House’s latest MFN-style deal with AstraZeneca following Pfizer. We’re joined by Incubate’s Policy Director John Guy to explain how “BIOSECURE” found new life inside the Senate’s NDAA and what that means for biopharma. We also cover...
Boston Biotech Pulse: Shutdowns, Pfizer Deal, and the Future of Innovation 09.10.2025 11:09
In this week’s episode, John Stanford reports from Boston - the beating heart of global biotech - with insights from investors, scientists, and executives shaping the future of life sciences. He breaks down what the government shutdown means for FDA operations, unpacks the White House–Pfizer deal, and shares key takeaways from conversations on U.S. competitiveness, biotech investment, and the next...
Government Shutdown, SBIR Expiration, and Trump’s Pharma Moves | Making Medicine Podcast 02.10.2025 8:31
This week, John Stanford breaks down the government shutdown and its impact on FDA, NIH, and biotech innovation. He also covers the surprising lapse of the SBIR program, what it means for early-stage biotech funding, and the fierce political debate around its future. Plus, we analyze President Trump’s deal with Pfizer on “Most Favored Nation” drug pricing and his latest tariff threats. What does a...
China’s Biotech Surge, GLP-1 Prices, & MFN Deadline | Press Pass with Max Bayer 25.09.2025 24:27
In this week’s episode, John Stanford breaks down the White House autism event, the debate over shifting SEC reports to twice-yearly, and how MFN pressure is reshaping pricing strategy - before welcoming Endpoints News’ Max Bayer for a wide-ranging Press Pass on tariffs, GLP-1s, and China’s biotech surge. We unpack what “success” might look like for the administration’s drug-pricing push, why insu...
UK Pharma Challenges, DTC Ads Debate & 5 New FDA Approvals | Making Medicine 18.09.2025 10:58
This week, John Stanford dives into the UK’s pharmaceutical challenges, including ABPI’s warning about declining competitiveness and major companies pausing investment. We also explore the debate over direct-to-consumer drug advertising in the U.S. and how it ties into investment decisions and the pill penalty. Finally, we close with August’s FDA approvals, celebrating breakthroughs for rare disea...
Ending the Pill Penalty on 9/13, Tariffs & FDA Rare Disease Guidance | Making Medicine 11.09.2025 8:21
In this week’s episode, John Stanford reflects on Incubate’s own holiday, September 13th (9/13), and the ongoing fight to end the pill penalty through the EPIC Act. He also covers the latest developments on tariffs, HHS hearings, FDA’s new rare disease principles, and the future of the SBIR program. We close with new research on how the IRA is affecting biotech investment. What are your thoughts o...
MassBio’s 2025 Snapshot: VC Gravity, Policy & a Competitiveness Playbook | Kendalle Burlin O’Connell 04.09.2025 25:31
This week, John Stanford sits down with Kendalle Burlin O’Connell (CEO & President, MassBio) to unpack the 2025 Industry Snapshot - why Massachusetts still attracts 22% of U.S. biotech VC and how advanced modalities keep the state at the cutting edge. We dig into the “flywheel” of the bioeconomy, from NIH and SBIR to FDA uncertainty, tariffs, and MFN. Kendalle lays out a unifying policy roadma...
Trump’s Tariffs, NIH Cuts, FDA Approvals & SBIR Debate | This Week in Making Medicine 28.08.2025 10:53
In this week’s episode, John Stanford breaks down the latest headlines across Washington, the FDA, NIH, and industry. We cover the Trump cabinet’s tariff-drug pricing push, BARDA’s funding of vaccine research following recent pivots away from mRNA vaccines, a hopeful return of biotech IPOs, and NIH program cuts. Plus, we debut the FDA Approvals Corner celebrating new medicines reaching patients, a...
Ned Sharpless on Biotech’s Future, HHS Shifts, and Global Competition | Making Medicine Podcast 21.08.2025 52:05
This week, John Stanford sits down with Dr. Ned Sharpless - former NCI Director, Acting FDA Commissioner, and now venture capitalist at Jupiter Bio Ventures. From the challenges of biotech funding, regulatory uncertainty, and the Inflation Reduction Act to the rise of China in biotech, IP battles, and the hype around AI, Ned offers candid insights you won’t hear anywhere else. What do you think ab...
FDA Shake-Ups & mRNA Funding Cuts | Industry Perspectives with Patrick Jordan 14.08.2025 21:39
In this episode, John Stanford dives into the latest policy and science headlines - from Dr. Vinay Prasad’s dramatic exit and return to the FDA, to HHS’s $500M cut in mRNA research, to looming pharmaceutical tariffs. Then, we debut our new "Industry Perspectives" segment with NovaQuest Capital’s Patrick Jordan, exploring how regulatory uncertainty, populist pricing policies, and global market dyna...
President Trump’s “Most Favored Nation” Drug Pricing Plan: Good Deal or Dangerous Gamble? 07.08.2025 17:05
This week on the Making Medicine Podcast, John Stanford dives into the “Most Favored Nation” (MFN) pricing concept, championed by President Trump, and what it could mean for drug pricing, innovation, and patients in America. Could aligning U.S. drug prices with those abroad actually save patients money, or would it crush innovation and access? John unpacks the trade-offs of MFN, the global free-ri...
Listener Q&A: Drug Price Controls, EU Tariffs, and the August Recess | Making Medicine Podcast 31.07.2025 10:13
In this week’s special Q&A episode, John Stanford tackles your biggest questions from around the biotech and policy world. From the growing list of drug price controls under the IRA to the newly announced 15% EU tariffs on medicines, there's a lot at stake for patients, companies, and innovation. John also breaks down the temporary NIH funding freeze, what it means for research, and why August...
Unpacking Uncertainty: Trump’s Health Policies & Future of FDA | Press Pass with Nyah Phengsitthy 24.07.2025 13:44
In this special Press Pass episode of the Making Medicine Podcast, John Stanford welcomes Nyah Phengsitthy of Bloomberg Law to break down the latest shifts in drug pricing, FDA policy, and the unpredictable pace of the Trump administration. They explore the Medicare drug price negotiation program, new FDA leadership under Dr. Makary, and the industry’s reaction to rapidly changing executive orders...
Trump’s 200% Pharma Tariff? Timeline, Impacts, and What Comes Next | Making Medicine Podcast 17.07.2025 11:21
In this week’s episode, John Stanford breaks down the evolving story of President Trump’s aggressive tariff strategy—focusing on a potential 200% tariff on pharmaceuticals. From a historical look at Trump’s decades-long affinity for tariffs to the current Section 232 investigation into pharmaceutical imports, we explore what these actions could mean for national security, drug prices, and innovati...
Big Beautiful Bill Breakdown, Orphan Cures Win, and What’s Next | Making Medicine Podcast Relaunch 10.07.2025 7:30
John Stanford kicks off the official relaunch of the Making Medicine Podcast with a deep dive into the "one big beautiful bill" that’s shaking up Washington. From major tax cuts to game-changing reforms like the Orphan Cures Act, this episode covers what’s in—and what’s not—in the sweeping legislation. What’s the real impact on biotech innovation, Medicaid, PBMs, and future drug pricing? John brea...
When Progress Gets Penalized: Biotech in the Age of IRA 18.04.2025 23:15
The path to new medicines is complex enough - policy doesn’t need to make it more difficult. But it does. In this episode, Thomas Kaiser , Co-Founder and Chief Scientific Officer Avicenna Biosciences joins the show to share how the Inflation Reduction Act is unintentionally discouraging investment in small-molecule drugs, creating the pill penalty. He explains why this matters not just to biotech...
Bridging Science and Business: A Conversation with Professor Fred Ledley 13.02.2025 43:15
In this episode of The Making Medicine podcast, John Stanford sits down with Professor Fred Ledley, Director of the Center for Integration of Science and Industry at Bentley University. Professor Ledley shares his journey from medical school to biotech entrepreneurship and academia, highlighting the critical intersection of science and business. The discussion explores the evolution of gene therap...
Can We Fix Healthcare? A Look Inside Our System 15.10.2024 18:59
The U.S. healthcare system is a puzzle for many. To fix it, we need smarter discussions and a deeper understanding of both the industry and the policies that shape it. In this episode, host John Stanford talks to healthcare policy expert Brian Reid , Principal at Reid Strategic and author of the Cost Curve newsletter , to discuss the challenges of fixing the incentives that have led to a broken he...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.